Rheumatoid arthritis
Reading File
Finding Sources
Searching PubMed
"rheumatoid arthritis"[MeSH Terms] AND treatment
Finding Sources
Finding Sources
Searching PubMed
"rheumatoid arthritis" AND ("treatment" OR "management")
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information to write a detailed answer. Let me compile everything into a thorough response.
Rheumatoid Arthritis (RA)
Definition and Overview
Rheumatoid arthritis is a chronic inflammatory systemic disease in which cellular and autoimmune mechanisms result in destruction of tissues, primarily the synovium. It is characterized by a destructive, symmetric polyarthritis associated with autoantibodies directed against citrullinated proteins. Manifestations vary from very mild, self-limited disease to multiorgan destruction and early death.
- Textbook of Family Medicine 9e, p. 882
Epidemiology
- Prevalence: 1-2% of adults (ranges from 0.3% in those under 35 to ~10% in those over 65)
- Female:male ratio = 3:1
- Peak incidence: ages 20-50 years
- Higher concordance in monozygotic vs. dizygotic twins, pointing to a strong genetic component (HLA-DR class II genes)
- Without treatment, more than 70% of patients with active, polyarticular, RF-positive RA develop joint damage or erosion within 2 years
Pathogenesis
Genetics and Environmental Triggers
The HLA-DR antigen (especially the "shared epitope" on HLA-DRB1) is the key genetic risk factor. Environmental and microbial triggers act on this genetic background:
-
Smoking is a key environmental risk factor. Smokers have higher levels of citrullinated peptides (57% vs. 7% in nonsmokers; P < 0.05) and increased PAD2 enzyme expression in the alveolar compartment, which promotes citrullination of proteins
-
Periodontitis - Porphyromonas gingivalis produces peptidyl arginine deiminase (PAD) enzymes, leading to citrullination of bacterial and host proteins; antibodies to this bacterium are found in 11-23% of RA patients
-
Gut microbiome - Prevotella copri enrichment is seen in patients with positive autoantibodies and in new-onset untreated RA
-
Firestein & Kelley's Textbook of Rheumatology, block5 / Rheumatology 2-Volume Set (2022), p. 476
The Citrullination Cascade
Citrullination (or deamination) is the post-translational modification that converts a positively charged arginine into a neutral citrulline residue, catalyzed by calcium-dependent peptidyl-arginine deiminase (PAD) enzymes. In genetically predisposed individuals, this triggers autoimmunity against citrullinated antigens.
Key anti-citrullinated protein antibodies (ACPAs) target:
- Citrullinated collagen type II
- Citrullinated fibrinogen
- Citrullinated vimentin
- Citrullinated alpha-enolase
The interaction between RA-associated MHC-II polymorphisms, smoking, and periodontal disease is linked to ACPA development.
- Rheumatology 2-Volume Set (2022), p. 476-477
Neutrophils and NETs
Neutrophils are abundant in inflamed RA joints, especially in early disease. Key mechanisms:
-
Patients have increased NET (neutrophil extracellular trap) complexes in circulation, correlating with ACPA levels and systemic inflammatory markers
-
NET formation releases active PAD isoforms that citrullinate extracellular histones and fibrinogen
-
NETs activate fibroblast-like synoviocytes (FLS), triggering release of pro-inflammatory cytokines, chemokines, and adhesion molecules
-
NET-derived elastase directly damages cartilage matrix
-
Firestein & Kelley's Textbook of Rheumatology, block3
Synovial Pathology
After an inciting event, synovial lining cells and subsynovial vessels proliferate, forming a pannus - invasive granulation tissue that invades and destroys cartilage and bone. The key cellular players:
| Cell | Role |
|---|---|
| Fibroblast-like synoviocytes (FLS) | Produce pro-inflammatory cytokines, matrix metalloproteinases (MMPs); epigenetically imprinted "inflammatory memory" via TNF |
| T cells (CD4+) | Drive adaptive immune response; CD4+CD28- senescent subset expanded in RA |
| B cells / plasma cells | Produce RF and ACPAs; form germinal centers in synovium |
| Macrophages | Major source of TNF, IL-1, IL-6 |
| Platelets / megakaryocytes | Thrombocytosis correlates with disease activity; platelet microparticles enter synovial fluid |
Key cytokines: TNF-alpha, IL-1, IL-6, IL-17 drive the inflammatory cascade and joint destruction.
Clinical Features
Articular Manifestations
- Symmetric synovitis is the hallmark
- Morning stiffness lasting >1 hour - classic feature, improves with activity
- Joints most commonly affected (in roughly decreasing order):
- Proximal interphalangeal (PIP) and metacarpophalangeal (MCP) joints
- Wrists, elbows, ankles, knees, metatarsophalangeal (MTP) joints
- Cervical spine (especially C1-C2, risking atlantoaxial subluxation)
- Shoulder, hip (less common)
- Synovial fluid: >2,000 WBCs/mm³, no crystals
Classic deformities (late disease):
- Swan-neck deformity - PIP hyperextension, DIP flexion
- Boutonnière deformity - PIP flexion, DIP hyperextension
- Ulnar deviation of fingers at MCPs
- Z-thumb deformity
Extra-articular Manifestations
| System | Manifestation |
|---|---|
| Skin | Rheumatoid nodules (20-30% of RF+ patients); vasculitis |
| Pulmonary | Interstitial lung disease (ILD), pleural effusion, pulmonary nodules, bronchiectasis |
| Cardiovascular | Accelerated atherosclerosis; RA is an independent CVD risk factor; pericarditis |
| Eyes | Keratoconjunctivitis sicca (secondary Sjögren), scleritis, episcleritis |
| Hematologic | Anemia of chronic disease; Felty's syndrome (RA + splenomegaly + neutropenia) |
| Nervous system | Peripheral neuropathy, cervical myelopathy (C1-C2 subluxation), carpal tunnel |
| Renal | Amyloidosis (AA type) in long-standing disease |
- Textbook of Family Medicine 9e, p. 883-884
Diagnosis
RA is a clinical diagnosis based on history, physical examination, and supported by labs and imaging. The ACR/EULAR 2010 Classification Criteria (score ≥6/10 = definite RA) are most widely used:
| Domain | Score |
|---|---|
| Joint involvement (1 large = 0; 2-10 large = 1; 1-3 small = 2; 4-10 small = 3; >10 including small = 5) | 0-5 |
| Serology (negative RF/ACPA = 0; low-positive = 2; high-positive = 3) | 0-3 |
| Acute-phase reactants (normal CRP and ESR = 0; abnormal = 1) | 0-1 |
| Duration of symptoms (<6 weeks = 0; ≥6 weeks = 1) | 0-1 |
Key Laboratory Tests
| Test | Significance |
|---|---|
| Rheumatoid Factor (RF) | Positive in ~70-80%; not specific; also positive in infections, other autoimmune conditions |
| Anti-CCP (ACPA) | More specific (~95%) for RA; indicates worse prognosis |
| ESR, CRP | Markers of inflammation and disease activity |
| CBC | Anemia of chronic disease, thrombocytosis in active disease |
| ANA | Often weakly positive; not diagnostic |
Imaging
- X-ray: Periarticular osteopenia (early) → joint space narrowing → erosions (bony erosions at joint margins are pathognomonic; appear months-to-1 year after onset)
- MRI: More sensitive for early synovitis, bone edema, erosions
- Ultrasound: Can detect synovitis and power Doppler signal
Management
Treatment Principles
- Treat-to-target (T2T) strategy - aim for remission or low disease activity
- Start disease-modifying therapy (DMARD) as soon as possible - before joint destruction
- Monitor with validated disease activity scores (DAS28, CDAI, SDAI)
- Regular monitoring for drug toxicity, infections, comorbidities
Step 1: NSAIDs
- For symptom relief (pain, stiffness)
- Do not prevent joint destruction
- NSAIDs are the preferred treatment for pain in RA (but DMARDs must be added)
Step 2: Conventional Synthetic DMARDs (csDMARDs)
| Drug | Notes |
|---|---|
| Methotrexate (MTX) | First-line DMARD; "anchor drug"; monitor LFTs, CBC; supplement with folic acid |
| Hydroxychloroquine | Mild disease; safe in pregnancy; retinal toxicity (rare) |
| Sulfasalazine | Often combined with MTX; GI side effects |
| Leflunomide | Alternative to MTX; teratogenic |
Combination csDMARD therapy (e.g., "triple therapy": MTX + HCQ + sulfasalazine) is effective for moderate-severe disease.
Step 3: Biologic DMARDs (bDMARDs)
Used when csDMARDs fail or for high disease activity. Usually combined with MTX:
| Class | Agents | Target |
|---|---|---|
| TNF inhibitors | Etanercept, infliximab, adalimumab, certolizumab, golimumab | TNF-alpha |
| IL-6 receptor inhibitor | Tocilizumab, sarilumab | IL-6R |
| T cell costimulation blocker | Abatacept | CD80/CD86 - CD28 |
| B cell depletion | Rituximab | CD20 on B cells |
| IL-1 inhibitor | Anakinra | IL-1R (less commonly used) |
Step 4: Targeted Synthetic DMARDs (tsDMARDs)
| Drug | Target | Notes |
|---|---|---|
| Tofacitinib | JAK1/3 | Oral; monitor for infections, thromboembolism |
| Baricitinib | JAK1/2 | Oral; approved for moderate-severe RA |
| Upadacitinib | JAK1 selective | Oral |
Glucocorticoids
- Low-dose prednisone (≤10 mg/day) for bridging therapy while DMARDs take effect
- Intra-articular injections for flares in specific joints
- Not for long-term monotherapy due to cumulative toxicity (osteoporosis, infection, metabolic effects)
Non-pharmacological Management
- Physical therapy and occupational therapy - joint protection, exercise, assistive devices
- Patient education - self-management, fatigue management
- Smoking cessation - reduces disease activity and ACPA levels
- Cardiovascular risk reduction - RA patients have elevated CVD risk requiring active management
- Osteoporosis prevention - calcium, vitamin D, bisphosphonates if indicated
- Surgery - synovectomy, joint replacement for refractory disease
Prognosis and Monitoring
- Poor prognostic factors: high RF/ACPA titers, elevated CRP/ESR, early erosions, >20 swollen joints, extra-articular disease
- Patients with active polyarticular seropositive RA have >70% chance of erosions within 2 years without treatment
- Disability and premature mortality (mainly cardiovascular) are significant without adequate therapy
- Regular monitoring for disease activity (DAS28), joint damage (imaging), and drug toxicity
Recent Evidence (PubMed, 2024-2026)
- DI Matteo & Emery (2024) - a comprehensive review of key clinical features and ongoing challenges in RA, highlighting that early treatment and treat-to-target strategies have transformed outcomes (Panminerva Med, PMID 39621317)
- Konzett & Aletaha (2024) - review of management strategies in RA emphasizing individualized treatment, T2T principles, and JAK inhibitor positioning (Nat Rev Rheumatol, PMID 39448800)
- Uke, Maharaj & Adebajo (2025) - updated epidemiology review noting evolving global prevalence trends (Best Pract Res Clin Rheumatol, PMID 39939219)
Sources:
- Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set (2022)
- Rheumatology, 2-Volume Set (2022, Elsevier)
- Textbook of Family Medicine 9e (Rakel)
This is a shared conversation. Sign in to Orris to start your own chat.